A method for inhibiting casein kinase I.epsilon. activity, comprising administering to said patient a therapeutically effective amount of a compound of formula I. ##STR00001## its stereoisomer, enantiomer, racemate, tautomer or pharmaceutically acceptable salt thereof.
Claims What is claimed is: 1. A method for inhibiting casein kinase I.epsilon. activity in a patient comprising the administration to said patient a therapeutically effective amount of a compound of formula I, or a stereoisomer, enantiomer, racemate, tautomer or a pharmaceutically acceptable salt thereof, ##STR00024## wherein X is H, Cl, F, Br, NO.sub.2, CN, OR.sup.2, NR.sup.2R.sup.2, HNSO.sub.2--C.sub.1-3alkyl, or NHCO--C.sub.1-3alkyl; Y is --S-- or --O--; R.sup.1 is 1) aryl, unsubstituted or substituted with one or more: a) C.sub.1-5alkoxy, b) OH, c) halogen, d) NR.sup.2R.sup.2, e) C.sub.1-5alkyl, unsubstituted or substituted with one or more: i) OH or ii) C.sub.1-5alkoxy; 2) a heterocycle, substituted or un-substituted with one or more: a) C.sub.1-5alkyl, substituted or un-substituted with one or more: i) OH or ii) C.sub.1-5alkoxy, b) C.sub.1-5alkoxy, c) OH, d) halogen, or e) NR.sup.2R.sup.2; 3) C.sub.1-5alkyl, substituted or un-substituted with one or more of: a) C.sub.1-5alkyl, b) C.sub.1-5alkoxy, c) OH, or d) aryl, substituted or un-substituted with one or more of: i) C.sub.1-5alkyl, ii) C.sub.1-5alkoxy, iii) OH, iv) halogen, or v) NR.sup.2R.sup.2; Z is 1) C(.dbd.O)NR.sup.2R.sup.3 or 2) C(.dbd.O)R.sup.4; R.sup.2 is hydrogen or C.sub.1-3alkyl; R.sup.3 is hydrogen, C.sub.1-5alkyl, or C.sub.3-6cycloalkyl; and R.sup.4 is 1-piperidinyl, 1-pyrrolidinyl, 1-piperazinyl or 4-morpholinyl, unsubstituted or substituted with one or more of: 1) C.sub.1-5alkyl, 2) C.sub.1-5alkoxy, 3) OH, 4) halogen, or 5) NR.sup.2R.sup.2. 2. The method as recited in claim 1 wherein the inhibition of casein kinase I.epsilon. activity results in altering of circadian rhythm period. 3. The method of claim 1 wherein Y is S, Z is C(.dbd.O)NHCH.sub.3, and R.sup.1 is phenyl or pyridinyl. 4. The method of claim 3 wherein the compound is selected from the group consisting of: 3-phenylsulfanyl-1H-indole-2-carboxylic acid methylamide, and 3-(pyridin-2-ylsulfanyl)-1H-indole-2-carboxylic acid methylamide. 5. The method of claim 1 wherein Y is O, Z is C(.dbd.O)NH.sub.2, and R.sup.1 is phenyl, substituted phenyl, C.sub.1-5alkyl or substituted C.sub.1-5alkyl. 6. The method of claim 5 wherein the compound is selected from the group consisting of: 3-phenoxy-1H-indole-2-carboxylic acid amide, 3-(4-methoxy-phenoxy)-1H-indole-2-carboxylic acid amide, 3-(4-fluoro-phenoxy)-1H-indole-2-carboxylic acid amide, 3-(2-fluoro-phenoxy)-1H-indole-2-carboxylic acid amide, 3-(4-chloro-phenoxy)-1H-indole-2-carboxylic acid amide, 3-methoxy-1H-indole-2-carboxylic acid amide, 3-ethoxy-1H-indole-2-carboxylic acid amide, 3-isopropoxy-1H-indole-2-carboxylic acid amide, 3-tert-butoxy-1H-indole-2-carboxylic acid amide, and 3-benzyloxy-1H-indole-2-carboxylic acid amide. 7. The method of claim 1 wherein: Y is S, Z is C(.dbd.O)R.sup.4, and R.sup.4 is 1-piperidinyl, 1-pyrrolidinyl, 1-piperazinyl or 4-morpholinyl. 8. The method of claim 7 wherein the compound is selected from the group consisting of: (5-fluoro-3-p-tolylsulfanyl-1H-indol-2-yl)-pyrrolidin-1-yl-methanone, (3-phenylsulfanyl-1H-indol-2-yl)-piperidin-1-yl-methanone, (5-fluoro-3-phenylsulfanyl-1H-indol-2-yl)-pyrrolidin-1-yl-methanone, [3-(2-amino-phenylsulfanyl)-1H-indol-2-yl]-pyrrolidin-1-yl-methanone, [3-(2-amino-phenylsulfanyl)-1H-indol-2-yl]-piperidin-1-yl-methanone, [3-(2-amino-phenylsulfanyl)-5-fluoro-1H-indol-2-yl]-piperidin-1-yl-methan- one, (3-phenylsulfanyl-1H-indol-2-yl)-piperazin-1-yl-methanone hydrochloride, [5-fluoro-3-(pyridin-2-ylsulfanyl)-1H-indol-2-yl]-pyrrolidin-1-yl-methano- ne, [3-(pyridin-2-ylsulfanyl)-1H-indol-2-yl]-pyrrolidin-1-yl-methanone, piperidin-1-yl-[3-(pyridin-2-ylsulfanyl)-1H-indol-2-yl]-methanone, and [5-fluoro-3-(pyridin-2-ylsulfanyl)-1H-indol-2-yl]-piperidin-1-yl-methanon- e. 9. The method of claim 1 wherein Y is S, Z is C(.dbd.O)NH.sub.2, and R.sup.1 is pyridinyl. 10. The method of claim 9 wherein the compound is 3-(pyridin-2-ylsulfanyl)-1H-indole-2-carboxylic acid amide. 11. The method of claim 1 wherein Y is S, Z is C(.dbd.O)NH.sub.2, and R.sup.1 is phenyl or substituted phenyl. 12. The method of claim 11 wherein the compound is selected from the group consisting of: 3-phenylsulfanyl-1H-indole-2-carboxylic acid amide, 5-bromo-3-phenylsulfanyl-1H-indole-2-carboxylic acid amide, 3-(2-amino-phenylsulfanyl)-5-methoxy-1H-indole-2-carboxylic acid amide, 3-(3-fluoro-phenylsulfanyl-1H-indole-2-carboxylic acid amide, 3-(2-amino-phenylsulfanyl)-5-bromo-1H-indole-2-carboxylic acid amide, and 3-(2-amino-phenylsulfanyl)-1H-indole-2-carboxylic acid amide. 